The Abbott Laboratories logo is displayed at the company's booth during the Consumer Electronics Show (CES) on January 5, 2022 in Las Vegas, Nevada. (Photo by Patrick T. FALLON / AFP) (Photo by ...
Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the Alinity i laboratory traumatic brain injury (TBI) blood test. This will be the first commercially available TBI ...
Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The North Chicago company said ...
Two years after Abbott landed FDA clearance for a hand-held blood test that could detect signs of mild traumatic brain injuries (TBIs) in the span of about 15 minutes, the concussion-spotting test is ...
By Sahil Pandey June 24 (Reuters) - ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories is rebounding from last year’s manufacturing ...
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...
On Jan. 24, Abbott posted its year-end and fourth-quarter numbers for the last three months of 2023. Revenue in Q4 rose by 1.5% year over year to $10.2 billion, but on an organic basis and when ...
The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results